The Value of a Restoration Team with Healthcare Experience

 

In this episode of Inside Restoration & Recovery, host Martha Lewis welcomes Jason McClaren, Director of Facilities Operations at Reunion Rehabilitation Hospitals, to discuss the critical advantage of partnering with a restoration team experienced in healthcare. A former firefighter and military veteran, Jason has spent the last decade managing safety, risk, and emergency preparedness across healthcare facilities.

He emphasizes the shift from reactive response—so familiar from his firefighting days—to proactive planning in healthcare. “We want to be ahead of the game,” Jason explains, describing how annual preparedness lunches with BMS CAT ensure contact lists, rapid‐response kits, and protocols are current before disasters strike.

A standout story recalls a Christmas Day flood when a vandal snapped a water dispenser off the wall, inundating the basement. Thanks to pre‐established relationships and rapid mobilization, BMS CAT arrived within hours, contained the water, installed temporary walls, and delivered a turnkey restoration—returning the facility to “like it never happened” in just weeks.

Jason also highlights infection control concerns—mold, smoke, odors—and how BMS CAT’s expertise and documentation rigor keep clinical spaces safe and compliant. He praises their ability to offer both emergency manpower and small‐scale remediation training for his in‐house team.

Watch More Episodes From This Series!

Recent Episodes

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…